Published in Hepat Res Treat on November 01, 2010
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Hepatitis C virus infection. N Engl J Med (2001) 18.67
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
The global burden of hepatitis C. Liver Int (2009) 8.89
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology (2007) 2.43
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37
Hepatocellular carcinoma: recent trends in Japan. Gastroenterology (2004) 2.35
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol (2008) 2.33
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl (2009) 1.76
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology (1997) 1.74
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology (2000) 1.72
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol (2004) 1.71
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl (2006) 1.67
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl (2008) 1.61
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl (2008) 1.59
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs (2009) 1.57
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl (2009) 1.55
Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis (2009) 1.53
Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl (2007) 1.51
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl (2003) 1.44
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis (2005) 1.44
The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant (2009) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol (2002) 1.43
Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology (1996) 1.42
Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol (2004) 1.42
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Hepatitis C and liver transplantation. J Hepatol (2001) 1.40
Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol (2005) 1.39
Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant (2006) 1.20
Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation (2006) 1.19
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology (2003) 1.19
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl (2007) 1.16
Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl (2009) 1.10
Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl (2008) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation (2004) 1.09
Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant (2006) 1.09
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant (2005) 1.08
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl (2004) 1.07
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat (2007) 1.04
The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology (1998) 1.03
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology (2000) 1.02
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation (2009) 1.00
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant (2009) 1.00
The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl (2009) 1.00
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl (2007) 0.99
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl (2006) 0.98
Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation (1998) 0.97
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation (2004) 0.94
Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol (2005) 0.93
Spontaneous clearance of hepatitis C virus infection post-liver transplantation is associated with rapidly changing quasispecies: a single case report. Liver Transpl (2000) 0.93
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl (2002) 0.92
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut (2007) 0.91
Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant (2004) 0.91
Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl (2003) 0.91
Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol (2004) 0.91
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl (2002) 0.90
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol (2005) 0.90
Future therapies for hepatitis C. Antivir Ther (2006) 0.90
A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology (2002) 0.89
Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation (2004) 0.89
Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc (2001) 0.89
Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl (2009) 0.89
Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol (2000) 0.88
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant (2006) 0.86
Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J Infect Dis (2007) 0.85
Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C. Gastroenterology (2007) 0.85
Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transplant (2005) 0.84
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer (2009) 2.54
Fluorescent cholangiography using indocyanine green for laparoscopic cholecystectomy: an initial experience. Arch Surg (2009) 2.48
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol (2012) 2.27
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg (2003) 2.01
Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends (2010) 2.01
Laparoscopic segmentectomy of the liver: from segment I to VIII. Ann Surg (2012) 1.99
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol (2013) 1.76
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol (2006) 1.72
Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery (2003) 1.67
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl (2004) 1.59
Intractable and rare diseases research in Asia. Biosci Trends (2012) 1.59
One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation (2007) 1.57
Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int (2008) 1.51
General rules for recording endoscopic findings of esophagogastric varices (2nd edition). Dig Endosc (2010) 1.51
Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.51
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology (2014) 1.47
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 1.44
Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. Clin Gastroenterol Hepatol (2011) 1.44
Laparoscopy-assisted hybrid left-side donor hepatectomy: is it truly less invasive for living donors? World J Surg (2014) 1.44
Two-stage pancreatojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results. Am J Surg (2008) 1.41
Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg (2015) 1.41
Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma (2010) 1.41
Laparoscopic hepatectomy under epidural anesthesia. Ann Surg (2014) 1.40
Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol (2010) 1.38
Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg (2004) 1.37
Usefulness of LigaSure for liver resection: analysis by randomized clinical trial. Am J Surg (2006) 1.35
Assessment of liver function for safe hepatic resection. Hepatol Res (2009) 1.34
Intraoperative fluorescent cholangiography using indocyanine green: a biliary road map for safe surgery. J Am Coll Surg (2008) 1.34
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery (2009) 1.29
Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci (2011) 1.28
Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg (2012) 1.28
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg (2014) 1.25
Virtual liver resection: computer-assisted operation planning using a three-dimensional liver representation. J Hepatobiliary Pancreat Sci (2013) 1.23
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol (2012) 1.19
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol (2009) 1.19
Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends (2010) 1.17
A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci (2012) 1.16
Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology (2009) 1.15
Risk factors and management of ascites after liver resection to treat hepatocellular carcinoma. Arch Surg (2009) 1.15
Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res (2010) 1.11
Anatomic resection of hepatocellular carcinoma: a step forward for the precise resection of the tumor-bearing portal territory of the liver. Ann Surg (2015) 1.10
Control arm for surgery alone is needed but difficult to obtain in randomized trials for adjuvant chemotherapy after liver resection for colorectal metastases. J Clin Oncol (2007) 1.10
MR imaging of the biliary tract with Gd-EOB-DTPA: effect of liver function on signal intensity. Eur J Radiol (2009) 1.10
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol (2011) 1.09
Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci (2010) 1.08
Estimation of portal uptake function in the venous congestive area after hemi-hepatectomy: postoperative contrast-enhanced magnetic resonance imaging and intraoperative indocyanine green-fluorescence imaging. J Hepatobiliary Pancreat Sci (2014) 1.08
Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol (2010) 1.08
Effects of middle hepatic vein reconstruction on right liver graft regeneration. Transplantation (2003) 1.08
Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg (2005) 1.08
Segmental resection of the third portion of the duodenum for a gastrointestinal stromal tumor: a case report. Jpn J Clin Oncol (2003) 1.07
Long-term survival in patients with locally advanced colon cancer after en bloc pancreaticoduodenectomy and colectomy. Dis Colon Rectum (2008) 1.06
Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol (2011) 1.06
Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg (2006) 1.05
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer (2013) 1.05
The intersegmental plane of the liver is not always flat--tricks for anatomical liver resection. Ann Surg (2010) 1.05
Visualization of subcapsular hepatic malignancy by indocyanine-green fluorescence imaging during laparoscopic hepatectomy. Surg Endosc (2014) 1.04
Vein reconstruction in modified right liver graft for living donor liver transplantation. Ann Surg (2003) 1.04
A worldwide survey of the current daily practice in liver surgery. Liver Cancer (2013) 1.04
The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int (2012) 1.04
Usefulness of multi-detector helical CT with multiplanar reconstruction for depicting the duodenal varices with multiple collateral shunt vessels. Hepatol Int (2010) 1.02
Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases. Ann Surg (2010) 1.02
Duct-to-duct biliary reconstruction in adult living-donor liver transplantation. Transplantation (2004) 1.01
Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol (2010) 1.01
Value of prophylactic abdominal drainage in 1269 consecutive cases of elective liver resection. J Hepatobiliary Pancreat Sci (2009) 1.01
Right lateral sector graft in adult living-related liver transplantation. Transplantation (2002) 1.00
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology (2006) 1.00
Liver Cancer Working Group report. Jpn J Clin Oncol (2010) 1.00
Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int (2010) 0.99
Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol (2005) 0.99
Systematic grading of surgical complications in live liver donors according to Clavien's system. Transpl Int (2006) 0.99